BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Biocryst Pharmaceuticals Inc.

Headquarters: Durham, NC, United States of America
Year Founded: 1986
Status: Public
Industry Sector: HealthTechnology
CEO: Jon P. Stonehouse
Number Of Employees: 580
Enterprise Value: $2,074,711,920
PE Ratio: -17.93
Exchange/Ticker 1: NASDAQ:BCRX
Exchange/Ticker 2: N/A
Latest Market Cap: $1,611,081,600

BioCentury | Mar 5, 2025
Management Tracks

CFO Anthony Doyle resigns at Biocryst

Plus: Greenside succeeds CEO Mark DePristo at Bighat, and updates from Be Biopharma, 3t and Imugene
BioCentury | Mar 31, 2023
Management Tracks

Amarin CEO Mikhail resigns, Kostas named chair

Plus: BioCryst appoints Hutson chair and updates from Flare, Mytide and TScan
BioCentury | Dec 16, 2022
Finance

Dec. 15 Quick Takes: Enlaza debuts with $61M, covalent targeting biologics platform

Plus: MinervaX taking strep vaccine to Phase II and updates from AbbVie, Prothena, Astria, Guardant and more
BioCentury | Sep 17, 2022
Product Development

HAE data clear Intellia’s path for liver knockout indications

The next test for Intellia will be whether it can achieve the same success with gene insertions
BioCentury | Sep 15, 2022
Management Tracks

New roles for Sheridan, Arnold at BioCryst

Plus Maltais joins XNK as CSO, and updates from HaYa, Ratio and more
BioCentury | Aug 16, 2022
Management Tracks

Simcha hires CEO, expands research agreement

Plus Integra’s Caruso passes away and updates from Ambrx, Cullinan, Zephyr, South Rampart and more
BioCentury | Aug 5, 2022
Finance

Aug. 4 Quick Takes: Forbion, Sofinnova lead F2G’s $70M financing

Plus newco emerges from Daley lab and updates Lilly, Pfizer, Regeneron, Arucs-Gilead, Travere, BioCryst and more
BioCentury | Apr 9, 2022
Finance

April 8 Quick Takes: Kaleido winding down operations

Plus: BioCryst loses $1.2B in market cap after pivotal pause and the latest in CEPI investments and more
BioCentury | Dec 3, 2021
Management Tracks

Sniecinski becomes CBO at Praxis

Plus: Monte Rosa, Taro, Point, Harbour and more
BioCentury | Nov 23, 2021
Product Development

Nov. 22 Quick Takes: GSK, Arrowhead in deal for NASH candidate

Plus Zenas-Xencor, BioCryst, Deciphera, bluebird, Exelixis and more
Items per page:
1 - 10 of 375